HISTORY AND ACHIEVEMENTS

Our Story: Funding Excellence in Cancer Research

A national 501(c)3 nonprofit organization founded in 1968, Cancer Research and Treatment Fund (CR&T) is a driving force in cancer research and treatment. Blood cancer research is our primary focus, but we believe that advances in this field can lead to important breakthroughs and a better understanding and treatment of allforms of cancer. For more than five decades, CR&T has funded the most promising physician-scientists, equipping them with resources to advance the treatment of blood cancers, including the myeloproliferative neoplasms (MPNs), leukemia, non-Hodgkin’s lymphoma, Hodgkin’s disease and multiple myeloma. We have also supported research into other common cancers, including breast, lung, and prostate cancer. We have invested in critical basic and clinical research projects.

 

CR&T-funded investigators are  aggressively pursuing biological, pharmacological and molecular solutions to key questions that enable us to understand cancer. They are working to design drugs and diagnostic tools based on this new knowledge. We recognize that this multidisciplinary approach offers the greatest promise of effective new therapies and, ultimately, cures.

Bringing Advances in Research to Cancer Patients

In 2000, CR&T was instrumental in establishing a Center for the Study of Leukemia and Myeloproliferative Neoplasms at Weill Cornell Medical College, a leading institution for cancer research in New York City.  On February 18, 2014, with a $3.7 million inaugural gift from CR&T, the Center was renamed the Richard T. Silver, MD Myeloproliferative Neoplasm (MPN) Center and reformulated as a translational research and treatment center.  CR&T continues to provide significant funding to the Silver Center, with the goal of building the world’s leading center dedicated to research into the MPNs, a group of rare blood cancers. Bringing laboratory results to patients and patient issues to the research lab, the Silver MPN Center generates cutting-edge discoveries that improve the health and quality of life of people with MPNs.

Funding Cancer Research: Innovative. Agile. Experienced.

CR&T has developed a reputation as an extremely independent and agile funding organization.  We intentionally avoid layers of bureaucracy so we can move swiftly and decisively, rapidly delivering funding for promising new cancer treatments.

Over the past 50 years, we have invested more than $15 million in research that has contributed to major advances in the fight against cancer.  Thanks to the generosity of our supporters and friends, CR&T-funded investigators have:

  • Conducted the initial clinical studies leading to the FDA’s approval of imatinib (Gleevec), a revolutionary drug used to treat chronic myeloid leukemia;
  • Participated in the development of new therapies for Hodgkin’s and non-Hodgkin’s lymphoma;
  • Contributed to the understanding of how and why breast cancers spread, and to the development of new breast cancer treatments;
  • Identified the processes of blood cell formation, leading to new treatments that block blood vessel growth in both blood and solid tumor cancers;
  • Helped discover the molecular mechanism that causes some patients to be resistant to ibrutinib, an important drug used to treat mantle cell leukemia; and
  • Contributed to the use of interferon alpha and other biologics in treating the myeloproliferative neoplasms (MPNs).

You can read more about our research achievements here.

Funding Research at World-Class Cancer Centers

CR&T has been a major source of funding for researchers on the frontlines of clinical research, awarding grants to investigators at such centers of excellence as Johns Hopkins University Medical Center, MD Anderson Cancer Center, Memorial Sloan-Kettering Cancer Center, and  Weill Cornell Medicine.

The Next 50 Years

Our history provides the background for our work and mission, but history isn’t nearly as important as the next breakthrough in cancer treatment and research. We invite you to make a donation and become a part of our story as we move forward together on the road to a cure.